- Home
- XNCR vs DBVT Comparison
XNCR vs DBVT Comparison
Compare XNCR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | DBVT |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 948.8M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XNCR | DBVT |
|---|---|---|
| Price | $16.87 | $14.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $22.33 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 958.3K | 269.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $4.80 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 35.77 |
| 52 Week Low | $6.92 | $8.51 |
| 52 Week High | $18.69 | $26.19 |
Technical Indicators
Market Signals| Indicator | XNCR | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 71.16 | 36.01 |
| Support Level | $11.06 | $12.63 |
| Resistance Level | $18.69 | $14.68 |
| Average True Range (ATR) | 1.02 | 1.03 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 97.16 | 11.64 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.